{"url":"https://newsforagent.com/news/2026-11-20/nemours-otarmeni-gene-therapy-hearing-loss","markdown_url":"https://newsforagent.com/news/2026-11-20/nemours-otarmeni-gene-therapy-hearing-loss.md","title":"Nemours Offers Otarmeni Gene Therapy for Child Hearing Loss","headline":"Nemours Children's Hospital Becomes First Southeast Center for Otarmeni Gene Therapy","description":"Nemours Children's Hospital in Orlando is the first Southeast authorized center for Otarmeni, an FDA-approved gene therapy for OTOF-related hearing loss in children.","section":"Expansion","published_at":"2026-11-20T17:52:57+00:00","modified_at":"2026-11-20T17:52:57+00:00","author":"News Desk","key_takeaways":["Nemours Children's Hospital in Orlando is the first activated authorized treatment center in the Southeast for Otarmeni, an FDA-approved gene therapy for OTOF-related hearing loss.","Nemours administered its first Otarmeni treatment outside a clinical trial on October 27 and is one of 11 authorized treatment centers nationwide.","In the CHORD trial, 16 of 20 children, or 80%, met the hearing-improvement threshold at 24 weeks."],"companies":[{"name":"Nemours","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000j4i/nemours","website":"http://www.nemours.org"},{"name":"Regeneron","is_primary":false,"profile_url":"https://akta.pro/company-profiles/000062c/regeneron","website":"http://www.regeneron.com"}],"source":{"publisher":"Yahoo","title":"Nemours Children’s Hospital offers new gene therapy for child hearing loss","url":"https://www.yahoo.com/news/science/articles/nemours-children-hospital-offers-gene-172956491.html"},"other_sources":[],"tags":["Expansion","Nemours","Regeneron"],"body_markdown":"[Nemours](https://akta.pro/company-profiles/0000j4i/nemours) Children's Hospital, Florida, announced Friday that it is the first activated authorized treatment center in the Southeast for Otarmeni, an FDA-approved gene therapy for hearing loss linked to changes in the OTOF gene. The Orlando hospital administered its first treatment outside a clinical trial on October 27, according to [Yahoo](https://www.yahoo.com/news/science/articles/nemours-children-hospital-offers-gene-172956491.html).\n\n## Nemours Becomes First Southeast Center for Otarmeni\n\nNemours said it is one of 11 authorized treatment centers nationwide for Otarmeni, which [Regeneron](https://akta.pro/company-profiles/000062c/regeneron) developed. The therapy delivers a working copy of the OTOF gene directly into the inner ear through a surgical procedure, helping produce a protein needed to transmit sound signals to the auditory nerve.\n\nThe FDA approved Otarmeni on April 23 for eligible children and adults with severe-to-profound hearing loss associated with mutations in both copies of the OTOF gene. Patients must retain certain inner-ear cell function and cannot have a previous cochlear implant in the ear being treated. Nemours said identifying eligible patients requires specialized hearing tests and genetic evaluation.\n\nNemours' Orlando and Jacksonville locations took part in the CHORD clinical trial that supported the treatment's accelerated approval. Among 20 children evaluated at 24 weeks, 16, or 80%, met the study's hearing-improvement threshold. Among a smaller group of 12 followed through 48 weeks, five, or approximately 42%, reached hearing levels described as normal.\n\nDr. Cedric Pritchett, chief of pediatric otolaryngology at Nemours Children's Hospital, Florida, said the designation builds on the hospital's involvement in the trial. \"We are honored to now offer families access to a therapy that addresses this underlying cause of hearing loss and has the potential to create life-changing opportunities for communication, learning and development,\" Pritchett said in the hospital's announcement.\n\n## Nemours' Gene Therapy and Home Care Programs\n\nNemours Children's Health introduced a gene therapy treatment for sickle cell disease at Nemours Children's Hospital in March 2026, building on a $10.5 million NIH grant awarded in 2021, according to akta.pro [company records](https://akta.pro/company-data). The same records show Nemours scaled its Advanced Care at Home program from a pilot in Florida in April 2025 to a multi-state operating model managing 150-160 pediatric patients daily across Delaware and Florida as of June 2026.\n\nNemours is a private pediatric health system founded in 1936 and headquartered in Jacksonville, with an estimated revenue of $1 billion to $5 billion and 5,001 to 10,000 employees, according to the same records.\n\n## Earlier Nemours Expansions\n\nNemours Children's Health opened a pediatric cardiology clinic in Bel Air, Maryland, on November 10, offering cardiac diagnostics, Holter and event monitors, ambulatory blood pressure monitoring, and consultations, with Dr. Robert Barlow as lead physician, Yahoo reported.\n\nNemours Children's Health received a five-year, $5.32 million NIH grant to expand sickle cell disease research, Beckershospitalreview reported on November 19. Nemours Children's Health also hosted the 2026 Pediatric Advanced Care at Home Conference to advance a national pediatric home care model, PR Newswire reported on November 12.\n\n## What Comes Next for Otarmeni\n\nContinued approval of Otarmeni may depend on further confirmation of lasting hearing improvements and benefits for speech development and quality of life, according to the FDA. Reported side effects included middle-ear infections, nausea, dizziness and procedural pain.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}